Using adavosertib-encapsulated MOFs for p53-mutated gallbladder cancer treatment via synthetic lethality
Since the revelation of poly(ADP-ribose) polymerase (PARP) inhibitors and their remarkable results in the treatment of BRCA1/2 mutant cancers, synthetic lethality (SL) in antitumor therapy has attracted increasing attention. ...